If the mass-production release is not closed before the next build, the unresolved points around trial acceptance, capability, and unresolved risks may create a production or quality risk.

PCBA Engineering & NPIMass Production ReleaseB1professional

หากการ Release Mass Productionยังไม่ปิดก่อน Build ถัดไป ประเด็นค้างเรื่อง ผล Trial, Capability และความเสี่ยงที่ยังเปิดอยู่ อาจสร้างความเสี่ยงต่อการผลิตหรือคุณภาพ

แกะรูปประโยค

สถานการณ์ / Intent

Risk communication

Grammar / Pattern

first conditional

คำศัพท์สำคัญ

mass-production release; trial acceptance, capability, and unresolved risks

ระดับภาษา

B1 · professional

ใช้ประโยคนี้อย่างไร

First Conditional + may เหมาะกับการอธิบายความเสี่ยงที่มีโอกาสเกิด แต่ยังไม่ควรพูดเป็นข้อเท็จจริงแน่นอน

พูด/เขียนได้หลายแบบ

FORMAL

Please ensure that the mass-production release is fully verified against the approved requirements for trial acceptance, capability, and unresolved risks before release.

CASUAL

Can we check the mass-production release and close the remaining points on trial acceptance, capability, and unresolved risks?

ALTERNATIVE

For the mass-production release, confirm the latest revision, the cut-in point, validation evidence, and any open risk before release.

Grammar Reference

First Conditional for Real Future RisksFirst Conditional สำหรับเงื่อนไขที่อาจเกิดจริงในอนาคต · If + present simple, will/can/may + base verb Zero Conditional for Rules and Repeated ResultsZero Conditional สำหรับกฎและผลที่เกิดเป็นประจำ · If/When + present simple, present simple

แกะรูปประโยค

ใช้ประโยคนี้อย่างไร

พูด/เขียนได้หลายแบบ

Grammar Reference

ประโยคใกล้เคียง

Do not release the mass-production release until the latest revision, cut-in point, validation evidence, and open risks have been reviewed with the responsible functions.

Before the next release, verify the controls for trial acceptance, capability, and unresolved risks in the mass-production release.

The team is reviewing the controls for trial acceptance, capability, and unresolved risks as part of the mass-production release.

We found a gap in the mass-production release: one or more controls related to trial acceptance, capability, and unresolved risks do not match the approved requirement.

We have completed the initial review of the mass-production release and assigned owners for the remaining actions related to trial acceptance, capability, and unresolved risks.

Could you clarify how the controls for trial acceptance, capability, and unresolved risks will be verified and who will approve the mass-production release?

We would appreciate it if you could provide the latest evidence for the mass-production release, including the status of trial acceptance, capability, and unresolved risks, by 3 p.m. today.

For management review, the main open point in the mass-production release is the control of trial acceptance, capability, and unresolved risks; the immediate risk is contained, and the team is working toward final closure.